Derivation and validation of cutoffs for clinical use of cell cycle arrest biomarkers

Acute kidney injury (AKI) remains a deadly condition. Tissue inhibitor of metalloproteinases (TIMP)-2 and insulin-like growth factor binding protein (IGFBP)7 are two recently discovered urinary biomarkers for AKI. We now report on the development, and diagnostic accuracy of two clinical cutoffs for...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nephrology, dialysis, transplantation Jg. 29; H. 11; S. 2054
Hauptverfasser:	Hoste, Eric A J, McCullough, Peter A, Kashani, Kianoush, Chawla, Lakhmir S, Joannidis, Michael, Shaw, Andrew D, Feldkamp, Thorsten, Uettwiller-Geiger, Denise L, McCarthy, Paul, Shi, Jing, Walker, Michael G, Kellum, John A
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England 01.11.2014
Schlagworte:	Acute Kidney Injury - pathology Acute Kidney Injury - urine Aged Biomarkers - urine Cell Cycle Checkpoints - physiology Female Follow-Up Studies Humans Insulin-Like Growth Factor Binding Proteins - urine Male Middle Aged Predictive Value of Tests ROC Curve Tissue Inhibitor of Metalloproteinase-2 - urine insulin-like growth factor binding protein (IGFBP)7 and tissue inhibitor of metalloproteinases (TIMP)-2 acute kidney injury acute renal failure sensitivity and specificity (MeSH) biomarkers
ISSN:	1460-2385, 1460-2385
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Acute kidney injury (AKI) remains a deadly condition. Tissue inhibitor of metalloproteinases (TIMP)-2 and insulin-like growth factor binding protein (IGFBP)7 are two recently discovered urinary biomarkers for AKI. We now report on the development, and diagnostic accuracy of two clinical cutoffs for a test using these markers. We derived cutoffs based on sensitivity and specificity for prediction of Kidney Disease: Improving Global Outcomes Stages 2-3 AKI within 12 h using data from a previously published multicenter cohort (Sapphire). Next, we verified these cutoffs in a new study (Opal) enrolling 154 critically ill adults from six sites in the USA. One hundred subjects (14%) in Sapphire and 27 (18%) in Opal met the primary end point. The results of the Opal study replicated those of Sapphire. Relative risk (95% CI) in both studies for subjects testing at ≤0.3 versus >0.3-2 were 4.7 (1.5-16) and 4.4 (2.5-8.7), or 12 (4.2-40) and 18 (10-37) for ≤0.3 versus >2. For the 0.3 cutoff, sensitivity was 89% in both studies, and specificity 50 and 53%. For 2.0, sensitivity was 42 and 44%, and specificity 95 and 90%. Urinary [TIMP-2]•[IGFBP7] values of 0.3 or greater identify patients at high risk and those >2 at highest risk for AKI and provide new information to support clinical decision-making. Clintrials.gov # NCT01209169 (Sapphire) and NCT01846884 (Opal).
Bibliographie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3
ISSN:	1460-2385 1460-2385
DOI:	10.1093/ndt/gfu292